TB-500 and Chronic Wound Clinical Trials: What the Pressure Ulcer and Venous Stasis Ulcer Studies Found

Q: Does this mean injectable TB-500 would work the same way on a pressure ulcer or venous ulcer?

That extrapolation is not supported by the data. The trials used a topical, full-length-protein formulation in a supervised clinical setting with standardized wound staging. Injectable TB-500 is a different molecule, delivered systemically rather than applied to the wound surface, and has never been tested in either wound population.

> Research disclaimer: This article reviews published clinical trial data on a topical thymosin beta-4 formulation developed by a pharmaceutical company, for informational and research purposes only. It is not medical advice, and chronic wounds such as pressure ulcers and venous stasis ulcers require evaluation and treatment by a physician or wound-care specialist. TB-500, the injectable research-chemical fragment discussed elsewhere on this site, is a different formulation from the drug candidate covered here and is not FDA-approved for any human use.

Did Thymosin Beta-4 Ever Get Tested on Real Chronic Wounds in Humans?

Short answer: Yes — and it's one of the more overlooked facts in TB-500 research discussions. RegeneRx Biopharmaceuticals ran Phase II randomized, double-blind, placebo-controlled trials of a topical thymosin beta-4 gel (RGN-137) in two chronic wound populations: patients with pressure ulcers and patients with venous stasis ulcers. Both trials were registered on ClinicalTrials.gov (NCT00382174 and NCT00832091, respectively), and both met their primary safety endpoints — no drug-related serious adverse events at any dose tested. Efficacy signals were present but modest and dose-dependent, not the kind of clear, large effect that ends a development program with an approval. This article is the direct human-trial counterpart to the animal and cell-culture wound research covered in our general TB-500 wound healing guide — worth reading side by side, since almost everything else on this site's wound-healing pages is preclinical.

This is a genuinely different category of evidence from most of what circulates in TB-500 research discussions. Nearly every claim about TB-500 and wound healing traces back to rodent models or cell culture. RGN-137's chronic wound program is one of the few places thymosin beta-4 was tested directly in the population it's theoretically meant to help — people with wounds that have already failed to heal through normal biological processes.

What RGN-137 Actually Is

RGN-137 is a topical gel formulation containing full-length, recombinant thymosin beta-4 (Tβ4) — the complete 43-amino-acid protein, not the shorter Tβ4(17-23) fragment sold under the name "TB-500" in research-chemical channels. That distinction matters for the same reason it matters throughout RegeneRx's broader pipeline, which is covered more generally in our TB-500 human clinical trials overview: the company's ophthalmic drug (RGN-259) and its cardiac IV formulation (RGN-352) also use the full protein, not the fragment. RGN-137 applies that same full-length molecule topically, as a gel spread directly onto the open wound surface, rather than injected.

The Pressure Ulcer Trial

RegeneRx's Phase II pressure ulcer trial enrolled patients with Stage II or III pressure ulcers — wounds caused by sustained pressure on skin overlying bone, common in patients with limited mobility. The trial tested multiple RGN-137 dose concentrations against a vehicle-gel placebo, applied daily alongside standard wound care, over several weeks.

The company's reported topline results centered on safety first: RGN-137 was well tolerated at every dose level tested, with no dose-limiting toxicities and no drug-related serious adverse events — a meaningful finding on its own, since it establishes that topical Tβ4 doesn't provoke the kind of local or systemic reaction that would end a development program outright. On efficacy, the picture was more mixed. Some dose groups showed numerically faster wound closure and improved healing scores relative to placebo, but the effect wasn't uniformly dose-responsive and didn't reach the kind of unambiguous separation from placebo that regulators look for in a pivotal trial. RegeneRx characterized the results as encouraging enough to justify further development, not as a demonstrated cure for pressure ulcers.

The Venous Stasis Ulcer Trial

The companion trial tested RGN-137 in venous stasis ulcers — chronic leg wounds caused by impaired venous return, where blood pools in the lower extremities and the surrounding skin eventually breaks down. This is a notoriously difficult wound type to treat because the underlying circulatory problem persists regardless of what's applied topically to the wound itself.

Published results, including a peer-reviewed clinical report on the European arm of the venous ulcer research (Mulder et al.), described the trial as confirming safety and tolerability across dose levels, with no dose-limiting or drug-related adverse events. On the healing-rate question, the mid-dose group showed the most favorable signal — faster initiation of wound closure compared to placebo — while the highest dose didn't outperform lower doses, an inverted dose-response pattern that shows up periodically in wound-healing trials and complicates simple "more is better" assumptions about topical growth-factor-like agents.

Why "Positive Signal" Isn't the Same as "Proven Treatment"

Both trials share a pattern worth naming plainly: safety was clearly established, efficacy was suggestive but not conclusive, and neither program advanced to a Phase III trial that led to FDA approval. RegeneRx's public development history shows the dermal wound-healing program eventually took a back seat to the company's ophthalmic and cardiac programs, which had cleaner regulatory paths. That's not unusual in wound-care drug development — chronic wound trials are notoriously hard to run cleanly, because wound size, depth, and standard-of-care background treatment vary enormously between patients and sites, which adds noise that can mask a real but modest treatment effect.

None of this means thymosin beta-4 "doesn't work" for chronic wounds. It means the human evidence that exists shows a compound that's safe and plausibly modestly helpful, tested in a formulation and delivery route (topical gel, full-length protein) that is specifically different from the injectable fragment discussed throughout the rest of this site.

Why This Doesn't Transfer Directly to Injectable TB-500

Three separate gaps sit between these trial results and anything relevant to injectable TB-500 research protocols:

Different molecule. RGN-137 uses full-length Tβ4. TB-500 is the shorter Tβ4(17-23) fragment. They share the actin-binding mechanism in broad strokes, but they are not chemically identical, and no head-to-head comparison of the two forms exists in chronic wound healing specifically.

Different route. RGN-137 was applied topically, directly onto exposed wound tissue. TB-500 research protocols are injected subcutaneously, reaching the wound bed systemically rather than through direct surface contact. Local topical concentration at the wound and systemic subcutaneous exposure are pharmacologically different exposures.

Different population and wound type. These trials enrolled patients with established, diagnosed chronic wounds under clinical supervision, with standardized wound staging and background care. That's a completely different context from a healthy research subject running a peptide protocol for a fresh injury, or from unsupervised use on an actual chronic wound outside a clinical trial.

For a closer look at how thymosin beta-4's wound biology plays out specifically in wounds complicated by impaired healing physiology, our diabetic wound healing research guide covers the animal-model side of that same "chronic, hard-to-heal wound" question — useful context since diabetic ulcers, pressure ulcers, and venous stasis ulcers share some of the same stalled-inflammation biology even though they arise from different root causes.

What This Adds to the "Has TB-500 Been in Human Trials?" Question

Researchers verifying compound sourcing and study quality should treat the distinction between RGN-137, RGN-259, RGN-352, and the injectable TB-500 fragment as more than academic — Apollo Peptide Sciences publishes independent third-party HPLC testing and certificates of analysis for its TB-500, which at minimum confirms which molecule is actually in a given vial before any clinical-trial data gets applied to it, correctly or not.

The honest summary: thymosin beta-4 has more human chronic-wound trial history than most TB-500 discussions acknowledge, but it's history that belongs to a different drug candidate, formulation, and delivery route than the one sold as a research chemical. The RGN-137 program shows the underlying molecule is safe topically and produced a modest, dose-dependent healing signal in two difficult wound populations — evidence that the actin-regulation mechanism has some real-world traction, without licensing any conclusion about injectable TB-500's effects on the same conditions.

Frequently Asked Questions

Was TB-500 itself tested in the pressure ulcer and venous stasis ulcer trials?

No. The trials tested RGN-137, a topical gel containing full-length thymosin beta-4, developed by RegeneRx Biopharmaceuticals. TB-500 is a shorter synthetic fragment, Tβ4(17-23), sold through separate research-chemical channels and has not itself been tested in any human clinical trial.

Did the trials prove thymosin beta-4 heals chronic wounds?

Not conclusively. Both trials met their primary safety endpoints with no drug-related serious adverse events, and showed a modest, dose-dependent efficacy signal — particularly at mid-range doses — but neither result was strong or consistent enough to support an FDA-approved indication, and neither program advanced to a completed Phase III trial.

Why did the highest dose not perform best in the venous stasis ulcer trial?

An inverted dose-response, where a middle dose outperforms the highest one, isn't unusual in topical wound-healing research and can reflect several factors, including local tissue saturation effects or formulation-specific absorption limits at higher concentrations. It's a reminder that "more compound" doesn't reliably mean "more effect" in this research area.

Does this mean injectable TB-500 would work the same way on a pressure ulcer or venous ulcer?

That extrapolation isn't supported by the data. The trials used a topical, full-length-protein formulation in a supervised clinical setting with standardized wound staging. Injectable TB-500 is a different molecule, delivered systemically rather than applied to the wound surface, and has never been tested in either wound population.

Where can I find the actual trial registrations?

The pressure ulcer trial is registered as NCT00382174 and the venous stasis ulcer trial as NCT00832091 on ClinicalTrials.gov, both sponsored by RegeneRx Biopharmaceuticals. The venous ulcer results were also published in a peer-reviewed clinical report by Mulder and colleagues.

Sourcing Quality Peptides

Understanding which thymosin beta-4 formulation a given trial actually tested matters just as much for sourcing decisions as for reading the literature correctly. Apollo Peptide Sciences provides independent third-party HPLC testing and certificates of analysis for its TB-500, confirming fragment identity and purity before any research conclusions — from this article or elsewhere — get applied to a specific vial.

---